|Mr. Jean-Louis Martin||Acting CEO & Director||N/A||N/A||N/A|
|Mr. Eric Moissenot||Gen. Director of Fin. & Admin.||N/A||N/A||N/A|
|Mr. Gérard Guillamot||Scientific Director||N/A||N/A||N/A|
|Mr. Christophe Eychenne-Baron||Head of R&D||N/A||N/A||N/A|
|Mr. Sebastien Taillemite||Deputy Managing Director of BU Fine Chemistry||N/A||N/A||N/A|
|Ms. Juliette Martin||Chief Exec. Officer of Protéus||N/A||N/A||N/A|
PCAS SA develops and produces complex molecules for life sciences and technologies. The company was founded in 1962 and is headquartered in Longjumeau, France. PCAS SA is a subsidiary of Seqens SAS
PCAS SA’s ISS governance QualityScore as of 1 December 2022 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 6.